Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.46

+5.6%

1:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Young who wrote (3597)	4/26/2001 9:02:26 PM
From: Biomaven	Read Replies (1) of 52153

<<SCIO>> And in today's CC they mentioned plans for later this year for the start of a Phase II for their P38 MAP kinase inhibitor. I think they said something like they have the data in hand from the Phase IB but have not released it yet. To me that sounds like the IB trial was a success. Tox issues have been very significant in other P38 programs, so if they have good results from the Phase I this is actually pretty important. VRTX when I last looked has one competitor in the clinic (seems to be moving kind of slowly) and two more in late pre-clinical. A successful drug in this area could well be a multi-billion dollar blockbuster, so stakes are very high. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next